Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
|---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. News
Apr 17, 2025 - globenewswire.com
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Apr 14, 2025 - globenewswire.com
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
Mar 20, 2025 - globenewswire.com
Can-Fite Partner Vetbiolix Accelerate Piclidenoson Development with Advanced Clinical Trial for Canine Osteoarthritis in a $3.8 Billion Market
Mar 19, 2025 - globenewswire.com
Can-Fite to Initiate Phase II Study in the Rare Genetic Disease Lowe Syndrome with Piclidenoson
Can-Fite BioPharma Ltd. Quantitative Score
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.
Can-Fite BioPharma Ltd. Earnings & Revenue
What’s This Company Really Worth? Find Out Instantly.
Warren Buffett’s go-to valuation method is Discounted Cash Flow (DCF). Our tool makes it effortless — no spreadsheets, just answers in a few clicks.
Can-Fite BioPharma Ltd. Financials
Table Compare
Compare CANF metrics with: | |||
|---|---|---|---|
Earnings & Growth | CANF | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | CANF | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | CANF | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | CANF | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Can-Fite BioPharma Ltd. Income
Can-Fite BioPharma Ltd. Balance Sheet
Can-Fite BioPharma Ltd. Cash Flow
Can-Fite BioPharma Ltd. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
| Metrics | Score |
|---|---|
| Discounted Cash Flows | Strong Sell |
| Return on Equity | Strong Sell |
| Return on Assets | Strong Sell |
| Debt/Equity Ratio | Buy |
| Price/Earnings Ratio | Strong Sell |
| Price/Book Ratio | Neutral |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Can-Fite BioPharma Ltd. Executives
| Name | Role |
|---|---|
| Mr. Motti Farbstein | Chief Executive Officer and Chief Financial & Operating Officer |
| Dr. Pnina Fishman Ph.D. | Founder, Chief Scientific Officer & Executive Chairperson |
| Dr. Sari Fishman Ph.D. | Vice President of Business Development |
| Dr. Stephen A. Harrison FACP, M.D. | Member of Clinical Advisory Board & Consulting Chief Medical Officer |
| Name | Role | Gender | Date of Birth | Pay |
|---|---|---|---|---|
| Mr. Motti Farbstein | Chief Executive Officer and Chief Financial & Operating Officer | Male | 1964 | 514K |
| Dr. Pnina Fishman Ph.D. | Founder, Chief Scientific Officer & Executive Chairperson | 1948 | 501K | |
| Dr. Sari Fishman Ph.D. | Vice President of Business Development | 1972 | 330K | |
| Dr. Stephen A. Harrison FACP, M.D. | Member of Clinical Advisory Board & Consulting Chief Medical Officer | -- |